Pipeline in a ProductTM

AMR Solutions

Superbug threat and the impending failure of old and trusted antibacterial agents led Bugworks to develop next-generation broad spectrum antibacterial agents with oral and intravenous options, to fight some of the most resistant superbugs around. Novelty in the design and mechanism of action has resulted in Gyrox.
illustration 2

Oncology solutions

Until recently, cytotoxic chemotherapy, surgery, radiotherapy and targeted therapies were the pillars of cancer treatment. Currently, immunotherapy & directed therapies have become the advanced pillars of oncology care.

Bugworks is leveraging this untapped potential to increase the response rate through our diverse, novel small molecule therapies.


to top